CORTIMENT®, a multi-matrix (MMX®) prolonged release budesonide, is indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis. Budesonide is a glucocorticoid used in the treatment of inflammatory bowel disease. It has a topical anti-inflammatory activity, but does not reduce cortisol levels to the same extent as systemic glucocorticoids. Cortiment has a controlled release throughout the whole colon.
CORTIMENT® MMX® (budesonide)* is indicated in adults for induction of remission in patients with active mild-to-moderate active ulcerative colitis.
CORTIMENT®MMX® contains budesonide, a locally acting glucocorticosteroid, in a novel, patented, oral tablet formulation utilizing MMX® multimatrix colonic delivery technology that is designed to result in the controlled release and distribution of budesonide throughout the length of the colon.
(*CORTIMENT®MMX® has been developed by Cosmo Pharmaceuticals S.A. Ferring is the licensee in the EU and Asia (excluding Japan), Australia, Canada, Latin America and Africa. In the United States, where the product is available as UCERIS®, the licensee is Salix Pharmaceuticals, Inc.
CORTIMENT is a trademark of Ferring B.V. MMX is a trademark of Cosmo Pharmaceuticals S.A. UCERIS is a registered trademark of Santarus, Inc, a wholly owned subsidiary of Salix Pharmaceuticals, Inc.)
All products passed Clinical Trials and registered in Russia.
24 May 2019
23 May 2019
22 May 2019
22 May 2019
This section contains professional specialized information. According to current legislation, the materials in this section can be accessed only by healthcare professionals. Are you a certified medical professional and do you agree with this statement?